PUBLISHER: Grand View Research | PRODUCT CODE: 1751269
PUBLISHER: Grand View Research | PRODUCT CODE: 1751269
The U.S. inhalation anesthesia market size is anticipated to reach USD 1.06 billion by 2030, growing at a CAGR of 6.1% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is attributed to the rising demand for shorter hospital stays and increasing surgical procedures. Inhalation anesthesia offers higher patient outcomes compared to intravenous anesthesia, as administering anesthetic agents through the respiratory tract allows for more controllable, effective sedation that is both cost-effective and safe.
Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.
According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.